{"organizations": [], "uuid": "9a21f0304592df23880090452561eb07a064184c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-6080/social", "site_section": "http://www.wsj.com/xml/rss/3_7014.xml", "section_title": "WSJ.com: US Business", "url": "https://www.wsj.com/articles/samsung-biogen-reach-deal-with-abbvie-to-sell-near-copy-of-humira-1522937627", "country": "US", "domain_rank": 387, "title": "Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-05T18:13:00.000+03:00", "replies_count": 0, "uuid": "9a21f0304592df23880090452561eb07a064184c"}, "author": "Imani Moise", "url": "https://www.wsj.com/articles/samsung-biogen-reach-deal-with-abbvie-to-sell-near-copy-of-humira-1522937627", "ord_in_thread": 0, "title": "Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira", "locations": [], "entities": {"persons": [{"name": "imraldi", "sentiment": "none"}, {"name": "abbvie", "sentiment": "none"}], "locations": [{"name": "humira", "sentiment": "none"}], "organizations": [{"name": "biogen reach deal with abbvie", "sentiment": "negative"}, {"name": "abbvie inc.", "sentiment": "negative"}, {"name": "samsung", "sentiment": "negative"}, {"name": "sell near copy of humira samsung bioepis co.", "sentiment": "negative"}, {"name": "biogen inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Samsung Bioepis Co. said Thursday it has reached a settlement with AbbVie Inc. that will allow it to market a near-replica version of one of the worldâ€™s top-selling drugs Humira.\nUnder the terms of the agreement, AbbVie will grant Samsung and its partner Biogen Inc. a nonexclusive license that allows the companies to sell their biosimilar version of the rheumatoid-arthritis treatment under the name Imraldi. AbbVie will also collect royalties from the companies once the product is launched.\n...  ", "external_links": [], "published": "2018-04-05T18:13:00.000+03:00", "crawled": "2018-04-05T19:52:42.070+03:00", "highlightTitle": ""}